MLSTF supports proof-of-concept projects at the early stages of translation that are of high risk but with potential of high reward. It funds researchers to accelerate the transition from discovery research to translational development projects by supporting preliminary work or feasibility studies to establish the viability of a translational approach.
This fund does not support exploratory basic science.
MLSTF is a consolidated fund comprising devolved funding from MRC Impact Acceleration Account, Wellcome IP Revenue Retention Funds, with some additional aligned funding. In 2025, the project managed fund will be in the region of £800,000 to ‘pump-prime’ the translation of novel therapeutics, devices, diagnostics and other therapeutic interventions (including ‘repurposing of existing therapies’) toward clinical testing.
In addition, we are pleased to confirm facilitated co-funding opportunities with Cancer Research Horizons (CRUK), and EPSRC IAA (administered by the MPLS Impact Office) and the University Challenge Seed Fund (USCF; administered by OUI).
Key Highlights
- Maximum funding volume per project up to £85k
- A dedicated route termed “Emerging Translational Innovators (ETI)” which provides an opportunity for early career researchers to use this fund as a stepping stone towards independently pursuing their translational research endeavours.
- Maximum number of applications permitted up to three per applicant (as PI, or Co-I)
| Application Deadline |
23/10/2025 17:00 |
| Application required? |
Apply Here |
